ライフサイエンスコーパス: sera

1 e presence of receptor-binding antibodies in sera.

2 utralization sensitivity to the early immune sera.

3 re, a similar pattern was seen in BE patient sera.

4 nvestigated anti-IgE autoantibodies in human sera.

5 gG1 binding to Mal d 1 in post-rBet v 1 SLIT sera.

6 , IL-18, and gamma interferon (IFN-gamma) in sera.

7 lizing activity present in SARS-CoV-2 immune sera.

8 examethylene reactivity was detected in 5/32 sera.

9 uld deplete the NAb activity from the rabbit sera.

10 uld be enhanced as well as reduced by immune sera.

11 ecognition of 22 enterococcal strains by the sera.

12 iomarkers for lung cancer detection in human sera.

13 ve samples and in 12 of 22 PRNT-seronegative sera.

14 uced by AQP4 rAbs and polyclonal NMO patient sera.

15 imicrobial activity in the presence of human sera.

16 s) allergens by western blot using patients' sera.

17 n transplant patients' and pregnant mothers' sera.

18 tection of GPI1-specific antibodies in human sera.

19 while acquiring reactivity to HPA-3b patient sera.

20 ted with higher T. gondii antibody levels in sera.

21 y 6.8% of systemic lupus erythematosus (SLE) sera.

22 utralizing activity of antibodies in patient sera.

23 dy titers from acute- and convalescent-phase sera.

24 etection of allergen-specific IgE in patient sera.

25 blotting with A. terreus susceptible patient sera.

26 significant difference between human and NWM sera.

27 even previously untested AChR-Ab positive MG sera, 10 AChR-Ab negative MG sera and 5 healthy control

28 Strains lacking yggS and serA (3-phosphoglycerate dehydrogenase) were conditional

29 he human virome in 492 clinical samples (384 sera, 92 pooled nasal and throat swabs, 10 stools, and 6

30 developed serum epitope repertoire analysis (SERA), a method to rapidly discover conserved, pathogen-

31 Reactivity of anti-B. miyamotoi sera against recombinant Vlps and the putative lipoprote

32 assessment of antiviral activity of patient sera against viral infection.

33 Postvaccination sera also prevented NS1-induced degradation of endotheli

34 Mass spectrometry analysis of patient sera also revealed an abnormal N-glycosylation profile f

35 Three other patients whose sera also showed strong immunoreactivity around 70kDa on

36 nd NS1 antibodies from ZIKV-infected patient sera, although lower cross-reactivity to DENV2/3-NS1 was

37 -Ab positive MG sera, 10 AChR-Ab negative MG sera and 5 healthy control sera were then applied to unc

38 All sera and 9/11 CSFs bound both the leucine-rich repeat (L

39 stimated from commercial laboratory residual sera and a community household survey in metropolitan At

40 ge-derived EVs accumulate in Er1(F/-) animal sera and are secreted in macrophage media after DNA dama

41 Sera and clinical data of 480 patients were available wh

42 ified four upregulated miRNAs in MFS patient sera and culture media of MFS cells.

43 Human vaccine sera and ferret antisera were analyzed by hemagglutinati

44 agreement across platforms for IgG-negative sera and for samples with intermediate to high levels of

45 show high sensitivity in convalescent-phase sera and high specificity for the Abbott, Euroimmun, and

46 The data indicate that sera and IgG from periodontitis subjects with elevated a

47 Post-IVIG PANDAS sera and IgG-depleted baseline sera did not alter the ac

48 ched membrane repair protein, in IIM patient sera and in our mouse model of IIM by ELISA.

49 ) in vitro, and IL-1alpha is elevated in the sera and liver of cachectic, suggesting a mechanism by w

50 itopes were mapped using milk-specific human sera and monoclonal antibodies on overlapping and recomb

51 etermined SARS-CoV-2-specific IgA and IgG in sera and mucosal fluids of 2 cohorts, including SARS-CoV

52 icle-mediated complement activation in human sera and plasma.

53 hese biosensors measured creatinine level in sera and urine samples and had storage stability between

54 o CHX ImmunoCAP was inhibited by ALX in 1/32 sera, and binding to PHMB was blocked by ALX (1/5) and b

55 d C-reactive protein (CRP), were elevated in sera, and correlated positively with increased disease b

56 xhibited high selectivity toward DA in human sera, and remained stable up to 3 months at 4 degrees C,

57 mplement activation in their lung, skin, and sera, and those individuals who were treated with comple

58 receptor and susceptibility to neutralizing sera, and tightened association of the S1 subunit with t

59 SARS-CoV-2 specific antibody titers in mouse sera, as well as robust neutralization of both a pseudo-

60 measured in maternal, cord blood, and infant sera at 3 and 6 months of age.

61 Immune sera broadly neutralized pseudoviruses with diverse SARS

62 Mapping the polyclonal sera by electron microscopy revealed that antibodies of

63 ytokines and chemokines were examined in the sera by ELISA and in skin biopsies by immunohistochemist

64 BPI and bacterial antigens were measured in sera by ELISA from five patient cohorts (n = 214).

65 s measured on maternal and cord blood/infant sera by multiplex Luminex assay; and the IgG threshold a

66 es of a large panel of COVID-19 convalescent sera can be assessed in a high-throughput fluorescent re

67 with more representative surveys, commercial sera can provide an approximate measure of seroprevalenc

68 Sera, cerebrospinal fluid (CSF) and tissue samples from

69 ) an immunology cohort, consisting of paired sera collected after PCR-confirmation of infection (n =

70 rus neutralizing antibodies were measured in sera collected before and one month after mOPV2 administ

71 Sera collected before emergence of SARS-CoV-2 (n = 224)

72 no significant difference in the ability of sera collected between 14 and 400 dpi to neutralize the

73 Saliva and sera collected from confirmed coronavirus disease 2019 (

74 nalysed HER2 gene CNV used qPCR method in 87 sera collected from GC and EGJC patients before surgical

75 sitivity and specificity of the assays using sera collected from pre-pandemic healthy controls, COVID

76 d a luciferase reporter virus to demonstrate sera collected from SARS and COVID-19 patients exhibited

77 n and 480 samples of prepandemic organ donor sera collected in 2010-2012.

78 unclustered AChRs, but 6/11 AChR-Ab positive sera compared with none of the 10 AChR-Ab negative sera

79 in humans, as healthy human and AAV patient sera contain anti-6PGD and anti-6PGD(391-410) antibodies

80 alysis demonstrated that melioidosis patient sera cross-reacted with OPSs of other Burkholderia speci

81 Baseline PANDAS sera decreased activity of striatal CINs, but not of par

82 tion of EV-transmitted VEGF-C from patients' sera demonstrates it is a reliable noninvasive way for c

83 Post-SLIT sera depleted of IgG1 or IgG4 were compared for their Ig

84 an Antonio type 2 (SA2) whole-cell proteins, sera derived from four dog groups were tested by WB to a

85 t-IVIG PANDAS sera and IgG-depleted baseline sera did not alter the activity of striatal CINs.

86 KD and matched febrile control sera did not demonstrate differences in antiviral antibo

87 iphtheria has been based on polyclonal horse sera directed against DT (diphtheria antitoxin; DAT).

88 Only post-rMal d 1 SLIT sera displayed IgE-blocking activity, which was signific

89 with presumptive TB, metabolic profiling of sera distinguished bacteriologically-confirmed and clini

90 ificities of epitopes targeted in polyclonal sera, elicited in immunized animals as well as in an HIV

91 A prospective cohort of bacteremic patient sera exhibited anti-BPI IgG responses in 23/154 (14.9%)

92 SARS-CoV-2-uninfected donor sera exhibited specific neutralizing activity against SA

93 trated that BPI autoreactivity in CF patient sera exhibits high avidity.

94 tor (IC(50) ~0.24 muM for C3 opsonization in sera), followed by SCR-1-2-3-4 (IC(50) ~0.6 muM), wherea

95 ntacts for testing by SARS-CoV-2 rRT-PCR and sera for SARS-CoV-2 antibodies testing by enzyme-linked

96 ns for IBH with seven of them binding IgE in sera from > 70% of the IBH-affected horses.

97 Sera from 12 NTM-PD patients due to Mycobacterium avium,

98 ization titers in pre- and post-immunization sera from 133 adults immunized with one of three types o

99 Additionally, sera from 16 (2.8%) HCWs demonstrated neutralization cap

100 CA19-9 levels were assessed in blinded sera from 175 subjects collected up to 5 years before di

101 The control group consisted of sera from 18 subjects allergic to peanut and/or tree nut

102 ens was analyzed by quantitative ELISA using sera from 18 subjects with a proven almond allergy.

103 virus disease 2019 (COVID-19), healthy donor sera from 2018, and a cross-reactivity serum panel colle

104 In a case-control study, sera from 254 subjects at clinical high risk (CHR) for p

105 an one expression system, were determined in sera from 347 horses.

106 We analyzed sera from 35 client-owned, 20 feral, and 30 specific pat

107 Sera from 387 patients with FEP (duration of psychosis <

108 gE binding was tested by means of ELISA with sera from 48 Ara h 2-sensitized patients with peanut all

109 Sera from 48 patients with anaphylaxis and 27 healthy su

110 We performed small RNA sequencing on sera from 492 children aged 5 to 12 years with mild-to-m

111 Sera from 5/8 KD patients day >= 8 after illness onset,

112 vated Sepharose, followed by incubation with sera from 55 Dutch peanut-allergic children and (125) I-

113 Sera from 763 representative subjects with serum samples

114 Analyzing sera from 97 US immigrants at various stages of M. tuber

115 ide programmable phage-display (PhIP-Seq) on sera from a cohort of people with APS1 and discovered mu

116 Longitudinal sera from a multicenter cohort of adult cardiac allograf

117 ty of NS1-specific IgG antibody responses in sera from a phase 2 clinical trial of Takeda's live-atte

118 E-reactivity and basophil degranulation with sera from all cyclophilin-positive patients.

119 Sera from almond-allergic subjects had significantly hig

120 Sera from animals administered dmAbs neutralized multipl

121 -2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients.

122 l trial data are needed to determine whether sera from COVID-19-convalescent patients and neutralizin

123 es and blocked CspZ FH-binding activity than sera from CspZ-immunized mice.

124 We found that the sera from CspZ-YA-vaccinated mice more efficiently elimi

125 Patient sera from days 1, 3, and 7 were assayed for IL-1beta and

126 orbent assay to measure anti-DENV NS1 IgG in sera from DENV-naive or preimmune subjects pre- and post

127 SCRs were added to lepirudin plasma or sera from different healthy subjects, to monitor nanopar

128 cell epitope mapping showed that compared to sera from experimentally infected animals, immunizations

129 Sera from hamsters infected with D614 virus exhibit mode

130 Using sera from HCMV+ glycoprotein B/MF59 vaccine recipients p

131 levels display marked subject variability in sera from healthy donors incubated at 37 degrees C.

132 atoid arthritis or multiple sclerosis) or in sera from healthy subjects with no evidence of disease.

133 slation of this effect to a vaccine setting, sera from human subjects before and after vaccination wi

134 pheral blood mononuclear cells (PBMCs) using sera from humans, several OWMs, and two New World monkey

135 Sera from IdeS-treated patients were also tested for All

136 Sera from imlifidase-treated patients were also tested f

137 etically distinct wild-type RVFV strains and sera from indigenous sheep and goat populations exposed

138 All candidates were recognized in sera from infected patients, and readily induced antibod

139 Passive transfer of sera from mice immunized with rewired virus vaccines sho

140 Sera from mice immunized with this antigen showed strong

141 IgE reactivity was assessed using sera from milk-sensitized donors in direct binding and i

142 sSiglec-8 levels were measurable in sera from most donors unrelated to absolute eosinophil c

143 yme-linked immunosorbent assay (ELISA) using sera from naive rabbits and rabbits with S. aureus-media

144 Sera from neutrophil-depleted mice had less antipneumoco

145 We analyzed sera from nonpregnant Colombians and Brazilians exposed

146 Sera from O. viverrini-infected and uninfected hamsters

147 In passive transfer experiments, sera from participants with high HAI activity efficientl

148 Sera from patients across the spectrum of TB were used t

149 d human serum rigorously characterized to be sera from patients with acute- and convalescent-phase ea

150 d targeted proteomics (N=625) of whole blood sera from patients with American College of Cardiology/A

151 ntibodies (anti-BC abs) were not detected in sera from patients with autoimmune diseases other than S

152 In contrast, sera from patients with bacteremia exhibited low avidity

153 1, were analyzed using a peptide library and sera from patients with clinical allergy to pine nut in

154 ty to bind IgE and IgG antibodies present in sera from patients with cow milk protein allergy using a

155 sensor was proven effective in real clinical sera from patients with satisfactory results.

156 of the human melanoma cell line C81-61 with sera from patients with the highest MDK levels promoted

157 successfully applied in HBV DNA detection in sera from patients without any amplification step (e.g.,

158 consisting of pre- and post-influenza season sera from PCR-confirmed influenza cases (n = 50), and (i

159 fluorescent immunoassay using three pools of sera from peach allergic patients.

160 (RBD) monoclonal antibodies and convalescent sera from people infected with either form of the virus.

161 Nonetheless, pooled sera from pre- and postchallenge groups, but not from co

162 oy the assay to measure receptor blocking of sera from SARS-CoV-2-infected patients.

163 omprised of global profiling of 376 miRNA in sera from SBNET patients (n = 11) versus healthy control

164 9 antibody activity was also observed in the sera from SLE patients compared with healthy people and

165 assay by measuring antibody functionality of sera from small animals and nonhuman primates immunized

166 cape that could compromise vaccine efficacy, sera from spike-immunized mice, nonhuman primates, and h

167 Antibody assays were conducted on sera from subjects reporting allergic reactions to mamma

168 ific anti-IgE autoantibodies were present in sera from subjects with allergy and subjects without all

169 Sera from TcI-endemic regions recognised gTSSA-I (74/146

170 d antibody titres are frequently elevated in sera from the acute-phase patients.

171 Examination of pre- and postchallenge sera from these mice revealed that immunization elicited

172 ct (P < .0001) and Pru du 6 (P < .0001) than sera from tolerant donors.

173 molecule array in 88 CSF, 348 plasma and 131 sera from treatment-naive RRMS patients (n=52), healthy

174 Passive transfer of sera from VSV-eGFP-SARS-CoV-2-immunized animals also pro

175 and trophoblast cells was similar to that in sera from wild-type virus-infected animals and dependent

176 graphy-mass spectrometry (GC-MS) analyses of sera from WT and Pax5+/- mice demonstrated the presence

177 However, SARS-CoV-2 sera generally lacked cross-neutralization to a highly h

178 mologous and heterologous strains, and their sera generated larger antigenic distances among strains.

179 None of the sera had detectable effects on desensitisation or recove

180 Animal sera have many disadvantages including serum sickness, b

181 aining 5 epitopes were recognized by patient sera IgE.

182 The maternal sera IgG threshold associated with 90% risk reduction wa

183 were significantly elevated in HS versus NC sera in Allo-CFC-1 (10 +/- 3% versus 2 +/- 1%, P = 0.001

184 n identifying B. microti antibody containing sera in an ELISA.

185 13 of 24 (54%) case patients with available sera, including 1 severely symptomatic, 9 mildly symptom

186 gens are up-regulated in cholestatic patient sera, including bile acids (BAs).

187 ations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second dose.

188 assays performed with fish-allergic patients sera indicated a 50% reduction in IgE-reactivity upon ED

189 Only 2/11 AChR-Ab positive sera inhibited AChR currents in unclustered AChRs, but 6

190 Still, immune sera inhibited HER2+ SKBR3 cell survival in a dose-depen

191 amongst mammals were altered in abundance in sera, irrespective of hemolysis in the samples.

192 and detectability of pegfilgrastim in human sera is also observed.

193 ught to persist for only 6-8 months in human sera, limiting the use of TgERP serology to only those p

194 l microbe Escherichia coli with pooled human sera markedly enhanced the capacity of monocytic APC to

195 alidated in additional SBNET (n = 33) and HC sera (n = 14); and then longitudinally after SBNET resec

196 pitope recognition was examined with patient sera (n = 31), CSFs (n = 11), longitudinal serum samples

197 Bacteremic patient sera (n = 32) exhibited IgG antibody autoreactivity agai

198 Contemporary human donor sera neutralized the group I human coronavirus NL63, but

199 Baseline sera obtained during a phase 2 safety/immunogenicity cli

200 gative, endothelial cell crossmatch-positive sera obtained from 12 cardiac allograft recipients at th

201 patients before surgical treatment and in 40 sera obtained from healthy donors.

202 Finally, human sera obtained from naturally acquired CHIKV infection cr

203 When paired sera obtained from seven patients with pemphigus foliace

204 Questionnaire data and sera obtained from the study subjects at the ages of 4,

205 Sera of 144 children with AD (age 0-3 years) were analyz

206 Sera of 4 patients with adult onset epilepsy and suspect

207 ed the prevalence of autoantibodies from the sera of 51 adult ICL patients (out of a cohort of 72).

208 ies directed to the ACE2IS from convalescent sera of 94 COVID-19-positive patients.

209 We report that sera of a subset of lupus patients contain autoantibodie

210 The sera of all 3 donors and their 10 paired recipients, pro

211 ug/ml) of these dmAbs were measured, and the sera of all animals displayed broad neutralizing activit

212 t mannose binding lectins (MBLs) and MBLs in sera of both murine and human origin bound to soluble an

213 bioactive IL-18 are detected, such as in the sera of Il-18bp knockout (KO) mice with CpG-induced macr

214 ced high titer of neutralizing antibodies in sera of immunized mice against pseudotyped lentivirus re

215 ares with S Typhimurium, were present in the sera of immunized mice but did not bind live intact Salm

216 ransplants from various donor strains and in sera of kidney transplant patients with high levels of H

217 Anti-MHC/HLA IgE levels were measured in sera of mice grafted with skin or heart transplants from

218 These APPs were not elevated in sera of patients with Alzheimer's Disease, frontotempora

219 es against GG and by human antibodies in the sera of patients with aspergillosis.

220 erved that non-desmoglein (Dsg) AuAbs in the sera of patients with Dsg1/3 AuAb-negative acute PV are

221 samples, including feces from stressed rats, sera of patients with kidney disease, and fermentation p

222 odies (IgG, IgA and IgM AAbs) present in the sera of patients with rheumatoid arthritis (RA).

223 In the sera of patients with talaromycosis, Mp1 protein (Mp1p),

224 The sera of seropositive children have neutralizing activity

225 des (ganglioside complex) in the acute-phase sera of some patients with GBS suggested the carbohydrat

226 Sera of SSc patients with anti-Scl70 Abs, at higher risk

227 i-CNS antibody reactivity was evident in the sera of the MS cohort, and the antibodies bound a hetero

228 were significantly higher than those in the sera of the offspring of dams immunized with DS-Cav1 VLP

229 The neutralizing antibody titers in the sera of the offspring of the dams immunized with UC-3 F

230 ocytosis assays showed that postimmunization sera opsonized T. pallidum Despite such promising result

231 ompared with none of the 10 AChR-Ab negative sera (p=0.0020) inhibited rapsyn-clustered AChR currents

232 Further, a serA pdxH strain, which accumulates PNP in the presence

233 od for strain-specific reference antigen and sera preparation for use with single-radial immunodiffus

234 Notably, sera produced against chimeric VLPs that presented swapp

235 NGS-based serology via SERA provides an effective approach to discover antigeni

236 and the virus neutralization test for sheep sera (R (2) = 0.75; 95% confidence interval [CI] = 0.73

237 nce interval [CI] = 0.73 to 0.92) and cattle sera (R (2) = 0.80; 95% CI = 0.67 to 0.97); in addition,

238 Hyperimmune sera raised against virus-like particles (VLPs) represen

239 ly high antibody responses and the resulting sera recognized neurofibrillary tangles and plaque-assoc

240 :16, while none of the 6 SARS-CoV-2-negative sera revealed neutralizing activity.

241 Together with a time series of sera samples from volunteers experimentally infected wit

242 Analysis of convalescent-phase sera showed high titers of GP38 antibodies indicating im

243 We tested patient sera, stool, and gastric aspirates using mouse bioassay

244 rotype-Ia and III IGbsD identified on infant sera supports the case for licensure of a GBS polysaccha

245 ndred and seven specimens are evaluated; 161 sera tested by PCR and IgM assays, 85 urines by PCR.

246 All sera tested from eight patients with pemphigus foliaceus

247 oncentration (EC50)-which is the dilution of sera that inhibits 50% infection in viral neutralization

248 s and severities), we generated two pools of sera that were analysed by a shotgun MS approach based o

249 Of the 11 sera that were false positive with ELISA, seven samples

250 METHODSWe hybridized 34 and 51 ICL patients' sera to a 9,000-human-proteome array and to a 128-known-

251 ") bilirubin (B(f) ) was measured in patient sera to characterize the binding of unconjugated bilirub

252 o examine the antigenic landscape in patient sera to facilitate investigation of the immune response

253 bated with Farage B (FB) cells with HS or NC sera to measure 7-AAD+ lysed FB cell%.

254 -HLA antibody positive (HS) or negative (NC) sera to measure IFNgamma+ NK cell%.

255 points after disease-onset, and seropositive sera to other human coronaviruses (CoVs).

256 We used paired human sera to screen for IgG with reactivity against six hCoVs

257 domains were used to raise specific rat anti-sera to select IEs with uniform expression of candidate

258 Cytotoxicity of OWM sera to TKO PBMCs was significantly greater than of huma

259 ng HLEC and melanoma cell lines with patient sera under both normoxia and IH.

260 omes were efficiently extracted from patient sera using anti-L1CAM conjugated zwitterionic polymer-mo

261 ecognition of gTSSA-I by non-endemic malaria sera was abolished by heat-denaturation.

262 gG1 binding to Mal d 1 in post-rMal d 1 SLIT sera was fully inhibited with rMal d 1 but not with rBet

263 d current inhibition by the AChR-Ab positive sera was greater when the AChRs were clustered (p=0.0385

264 t in recombinant form, to which 25/55 of the sera was IgE-positive.

265 Effective opsonophagocytic killing for the 2 sera was observed against different E. faecalis and E. f

266 on of virus-specific IgG antibodies from bat sera, we assess the level of serological cross-reactivit

267 tralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged S

268 Sera were analysed using (1)H nuclear magnetic resonance

269 Pre- and post-SLIT sera were assessed for rMal d 1-specific IgG antibodies

270 Plasma/sera were collected at baseline, and 1, 3, 6 and 12 mont

271 Sera were collected from participants and batch tested b

272 elis; 3 months later, stomachs, spleens, and sera were collected, along with macrophages derived from

273 outbreaks, as well as acute and convalescent sera were collected.

274 Patient and matched healthy donor (HD) sera were derived from four large cohorts: 1) rheumatoid

275 Titration curves of hyperimmune sera were included on assay plates, assay signals underw

276 pes that are unique to the protective rabbit sera were mapped.

277 The antibody titers in the prechallenge sera were not predictive of protection.

278 Sera were obtained from 1106/1110 children.

279 -free survival, and IGFBP7 levels in patient sera were shown to be higher after relapse.

280 Sera were taken at multiple times during the vaccination

281 Sera were tested for AQP4-IgG and MOG-IgG by using a liv

282 Sera were tested in haemagglutination inhibition assay.

283 hR-Ab negative MG sera and 5 healthy control sera were then applied to unclustered and rapsyn-cluster

284 applied to the analysis of pancreatic cancer sera, where Tn-glycoproteins were identified.

285 MKs specifically reacted with HPA-3a patient sera, whereas the HPA-3b MKs lost reactivity with HPA-3a

286 est results occurred in approximately 11% of sera, which had low levels of neutralizing antibody.

287 mentation with human AAT protein pooled from sera, which is only reserved for patients with advanced

288 g:neutralizing ratio than convalescent human sera, which may minimize the risk of vaccine-associated

289 at of a panel of COVID-19 convalescent human sera, which were obtained at least 14 days after a posit

290 A-3b MKs lost reactivity with HPA-3a patient sera while acquiring reactivity to HPA-3b patient sera.

291 Recently, we showed how sera with 20 to 30% neutralization breadth could, nevert

292 We found that patient sera with elevated levels of TRIM72 autoantibodies suppr

293 significant cross-reactivity of RF+ patient sera with fibrinogen in both western blots and ELISAs.

294 I activity efficiently protected mice, while sera with low HAI activity protected mice to a lower ext

295 no cross-reactivity could be detected among sera with other infections.

296 Patient sera with significantly reduced anti-HLA antibody levels

297 Depletion of human sera with trimer caused reductions in NAbs similar to th

298 re neutralizing antibody activity in patient sera within 5 hours, and it produces results in concorda

299 ence of yggS, exhibited similar phenotype to serA yggS mutant.

300 ional lethality observed in the glyA yggS or serA yggS mutants.